帕比司他|T2383

Panobinostat
404950-80-7

￥153 1mg 起订

￥335 5mg 起订

￥526 10mg 起订

上海更新日期：2024-09-14

TargetMol中国（陶术生物）

VIP12年

联系人：邵小姐

电话：021-021-33632979拨打

手机：15002134094 拨打

邮箱：marketing@targetmol.com

产品详情:

中文名称：: 帕比司他

英文名称：: Panobinostat

CAS号：: 404950-80-7

品牌：: TargetMol

产地：: 美国

保存条件：: Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice.

纯度规格：: 99.14%

产品类别：: 抑制剂

货号：: T2383

Product Introduction

Bioactivity

名称	Panobinostat
描述	Panobinostat (NVP-LBH589) is a broad-spectrum HDAC inhibitor (IC50=5 nM) with oral activity and non-selectivity. Panobinostat has antitumor activity and induces apoptosis and autophagy.
细胞实验	Blasts from peripheral blood of 2 patients and from bone marrow of 4 patients were isolated with Ficoll-Hypaque, put in culture at a density of 500?000 cells/mL with RPMI-1640 medium containing 10% fetal bovine serum and 50 units/mL penicillin and streptomycin, and treated with different doses of LBH589 (0-100 μM) for up to 48 hours [1].
动物实验	AE17 and TC-1 cancer cells (1 × 10^6 cells) were injected into the flanks of adult female C57Bl/6 mice and severe combined immunodeficiency (SCID) mice. M30 (10 × 10^6 cells), A549 (5 × 10^6 cells), H69 (2.5 × 10^6 cells), BK-T (6.5 × 10^6), H526 (10 × 10^6), and RG1 (10 × 10^6) cells were also injected, but in the presence of matrigel (BD Biosciences), into the flanks of SCID mice. There were 5 to 10 mice in each treatment group. The experiments with the A549 and H69 cell lines were repeated to ensure the statistical consistency of the results. Experiments were terminated when the tumors in the control mice had grown to a size that threatened the quality of life of the mice. When tumors reached 100 to 500 mm3, panobinostat was administered via i.p. injections (10–20 mg/kg) on a daily schedule (5-days-on, 2-days-off regimen) for the entire duration of the experiment. Control mice received i.p. injections with dextrose 5% in water ("vehicle treatment"). Every tumor was measured with a caliper at least twice weekly. For evaluation of the effects of combination therapy on SCLC-derived tumors, SCID mice with H69 tumors were administered panobinostat as described above. Three days after the initiation of panobinostat, and again 1 wk later, etoposide (40 mg/kg) was administered i.p [3].
体外活性	方法：37 种肺癌细胞系用 Panobinostat (0-800 nmol/L) 处理 48-72 h，使用 MTT 方法检测细胞活力。结果：Panobinostat 对人和小鼠的肺癌细胞系表现出强大的抗增殖活性和细胞毒性。[1] 方法：人 ALL 细胞 MOLT-4 和 Reh 用 Panobinostat (10-100 nM) 处理 24-72 h，使用 Flow Cytometry 检测细胞凋亡情况。结果：Panobinostat 以时间和剂量依赖的方式诱导 MOLT-4 和 Reh 细胞的凋亡。[2]
体内活性	方法：为检测体内抗肿瘤活性，将 Panobinostat (20 mg/kg) 腹腔注射给携带人 SCLC 肿瘤 H526、BKT、RG1 或 H69 的 SCID 小鼠，每周五次，持续两周。结果：Panobinostat 显著减缓源于 SCLC 细胞的肿瘤的体内生长并诱导缓解。[1] 方法：为研究对中风后增强运动功能恢复的潜力，将 Panobinostat (3-10 mg/kg) 腹腔注射给中风的 CD-1 小鼠，每两天一次，持续十天。结果：体育锻炼与 Panobinostat 的结合都不会对中风后小鼠的运动恢复产生实质性影响。Panobinostat 治疗加上有限的身体康复不太可能为患有运动功能障碍的中风幸存者提供治疗方式。[3]
存储条件	Powder: -20°C for 3 years \| In solvent: -80°C for 1 year \| Shipping with blue ice.
溶解度	H2O : < 1 mg/mL (insoluble or slightly soluble) 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 6.4 mg/mL (18.32 mM), Please add co-solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. Ethanol : < 1 mg/mL (insoluble or slightly soluble) DMSO : 16.67 mg/mL (47.7 mM)
关键字	Human immunodeficiency virus \| Histone deacetylases \| NVP-LBH 589 \| HIV \| HDAC \| Autophagy \| inhibit \| Inhibitor \| Panobinostat \| LBH-589 \| Apoptosis \| NVP-LBH-589 \| LBH 589
相关产品	Guanidine hydrochloride \| Naringin \| Valproic Acid \| L-Glutamic acid \| Emtricitabine \| Hydroxychloroquine \| Lamivudine \| Dextran sulfate sodium salt (MW 4500-5500) \| Stavudine \| L-Ascorbic acid \| Paeonol \| Sodium 4-phenylbutyrate
相关库	抗癌上市药物库 \| 经典已知活性库 \| 抗癌活性化合物库 \| 已知活性化合物库 \| EMA 上市药物库 \| 抗病毒库 \| FDA 上市药物库 \| 药物功能重定位化合物库 \| 抗癌临床化合物库 \| 抗癌药物库

帕比司他|||NVP-LBH589|||LBH589|TargetMol

上海陶术生物科技有限公司为美国Target Molecule Corp. ( Target Mol ) 在上海建立的全资子公司。我们与美国波士顿、德国慕尼黑的同事一起，为北美、欧洲和亚洲从事药物研发和生物学研究的科学家提供优质的产品和专业的服务。公司下设筛选事业部，化学事业部，生物事业部和新材料部。从虚拟筛选到实体化合物分子供应；从商业化产品销售到个性化定制合成；从对明确靶点的分子筛选到对明确分子的多靶点筛选，从高通量筛选到化学结构优化，我们都可以满足您的科研用品及技术服务的需求。经过在中国市场五年的精心耕耘，我们已成为筛选化合物领域优秀的供应商，为超过五百家学校和各类企业提供了品质卓越的小分子化合物和药物筛

成立日期	(12年)
注册资本	566.2651万人民币
员工人数	100-500人
年营业额	￥ 1亿以上
经营模式	贸易,试剂,定制,服务
主营行业	化学试剂,生物活性小分子